Daniel Albert M.D., M.S.

1. RO1 NIH application: The Molecular Biology of Retinoblastoma. The major goals in this study are to examine the molecular biology of the two most common intraocular malignancies in man using transgenic mouse models and to devise treatment strategies for these tumors.

2. U10 NIH continuing grant: Collaborative Ocular Melanoma Study: Pathology Center. Dr. Albert's Ophthalmic Pathology Lab also serves as Pathology Center for a national clinical trial for the treatment of ocular melanoma. The principle activity at this time is the study of mortality and metastases in these patients.

3. Pharmacia-Upjohn; Latanoprost Pathology Studies. Iridectomy specimens and autopsy eyes from patients treated with a glaucoma drug (latanoprost) will be examined. Dr. Albert also chairs the International Latanoprost Study Group to discuss and review all histopathologic data from patients treated with latanoprost worldwide.

Richard R. Dubielzig, DVM

1. Factors affecting survival in canine and feline melanocytic ocular neoplasia.

2. Morphology of ocular disease in early stages of glaucoma.

3. Feline ocular lymphosarcoma.

4. Feline post-traumatic sarcoma.

Chris Murphy, DVM, Ph.D.

1. Interdisciplinary research on the modulation of cell behavior by nanoscale topographic features. This is being carefully explored with a view towards applying findings to the development of improved prosthetic devices.

2. Interdisciplinary research on the application of liquid crystal reporting systems to biology.

3. The optimization of organ storage for transplantation by the use of trophic factors.

4. Corneal wound healing: understanding the underlying mechanisms in spontaneous chronic corneal epithelial defects (SCCED) in dogs and the modulation of wound healing by treatment with trophic factors.

5. Projects in comparative physiological optics.

Robert Nickells Ph.D.

1. Molecular biology of retinal ganglion cell death.

2. Role of cell cycle regulatory genes in proliferative and degenerative ocular disease.

3. Changes in photoreceptor gene expression in glaucoma.

4. Identification of glaucoma susceptibility factors in mice.

Ted Reid Ph.D.

1. Use of anti-sense DNA to modulate retinal membrane cell growth.

2. The use of defensin peptides for tissue preservation.

3. The modulation of diabetic wound healing by the use of neuropeptides.

4. The use of organo-selenium compounds to block biofilm formation on biodevices.

5. The use of selenium modified antibodies to specifically inhibit cancer cell growth.

6. Determination of the mechanism of formation of pterygia.

Go to top